The psychometric properties of the St George’s Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review

Health and Quality of Life Outcomes

Kevin K Brown²  Craig S Conoscenti³  Dirk Esser¹  Jeffrey J Swigris² 

[1]Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany

[2]National Jewish Health, Denver, CO, USA

[3]Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA

关键词: Reliability;    Validity;    Psychometrics;    HRQL;    Health-related quality of life;    SGRQ;    St George’s Respiratory Questionnaire;    PROs;    Patient-reported outcomes;    Idiopathic pulmonary fibrosis;   

Others  :  1164538
DOI  :  10.1186/s12955-014-0124-1

 received in 2014-04-25, accepted in 2014-08-05,  发布年份 2014

【 摘 要 】

Assessment of health-related quality of life (HRQL) is particularly important in patients with progressive and incurable diseases such as idiopathic pulmonary fibrosis (IPF). The St George’s Respiratory Questionnaire (SGRQ) has frequently been used to measure HRQL in patients with IPF, but it was developed for patients with obstructive lung diseases. The aim of this review was to examine published data on the psychometric performance of the SGRQ in patients with IPF. A comprehensive search was conducted to identify studies reporting data on the internal consistency, construct validity, test-retest reliability, and interpretability of the SGRQ in patients with IPF, published up to August 2013. In total, data from 30 papers were reviewed. Internal consistency was moderate for the SGRQ symptoms score and excellent for the SGRQ activity, impact and total scores. Validity of the SGRQ symptoms, activity, impact and total scores was supported by moderate to strong correlations with other patient-reported outcome measures and with a measure of exercise capacity. Most correlations were moderately strong between SGRQ activity or total scores and forced or static vital capacity, the most commonly used marker of IPF severity. There was evidence that changes in SGRQ domain and total scores could detect within-subject improvement in health status, and differentiate groups of patients whose health status had improved, declined or remained unchanged. Although the SGRQ was not developed specifically for use with patients with IPF, on balance, its psychometric properties are adequate and suggest that it may be a useful measure of HRQL in this patient population. However, several questions remain unaddressed, and further research is needed to confirm the SGRQ’s utility in IPF.

【 授权许可】

   
2014 Swigris et al.; licensee Biomed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, et al.: An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824.
• [2]Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D: Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev 2012, 21:355-361.
• [3]Ley B, Collard HR, King TE Jr: Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011, 183:431-440.
• [4]Swigris JJ, Stewart AL, Gould MK, Wilson SR: Patients’ perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives. Health Qual Life Outcomes 2005, 3:61. BioMed Central Full Text
• [5]Swigris JJ, Kuschner WG, Jacobs SS, Wilson SR, Gould MK: Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review. Thorax 2005, 60:588-594.
• [6]Belkin A, Swigris JJ: Health-related quality of life in idiopathic pulmonary fibrosis: where are we now? Curr Opin Pulm Med 2013, 19:474-479.
• [7]Swigris JJ, Gould MK, Wilson SR: Health-related quality of life among patients with idiopathic pulmonary fibrosis. Chest 2005, 127:284-294.
• [8]Swigris JJ, Fairclough D: Patient-reported outcomes in idiopathic pulmonary fibrosis research. Chest 2012, 142:291-297.
• [9]Jones PW, Quirk FH, Baveystock CM: The St George’s Respiratory Questionnaire. Respir Med 1991, 85:25-31.
• [10]Yorke J, Jones PW, Swigris JJ: Development and validity testing of an IPF-specific version of the St George’s Respiratory Questionnaire. Thorax 2010, 65:921-926.
• [11]Hays R, Revicki DA: Reliability and validity (including responsiveness). In Assessing quality of life in clinical trials. 2nd edition. Edited by Fayers P, Hays R. Oxford University Press, New York; 2005:25-39.
• [12]Hinkle D, Wiersma W, Jurs S: Applied statistics for the behavioral sciences. Houghton-Mifflin, Boston; 1988.
• [13]Antoniou KM, Nicholson AG, Dimadi M, Malagari K, Latsi P, Rapti A, Tzanakis N, Trigidou R, Polychronopoulos V, Bouros D: Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis. Eur Respir J 2006, 28:496-504.
• [14]Berry CE, Drummond MB, Han MK, Li D, Fuller C, Limper AH, Martinez FJ, Schwarz MI, Sciurba FC, Wise RA: Relationship between lung function impairment and health-related quality of life in COPD and interstitial lung disease. Chest 2012, 142:704-711.
• [15]Chang JA, Curtis JR, Patrick DL, Raghu G: Assessment of health-related quality of life in patients with interstitial lung disease. Chest 1999, 116:1175-1182.
• [16]Du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE Jr: Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011, 183:1231-1237.
• [17]Han MK, Bach DS, Hagan PG, Yow E, Flaherty KR, Toews GB, Anstrom KJ, Martinez FJ: Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Chest 2013, 143:1699-1708.
• [18]Horton MR, Santopietro V, Mathew L, Horton KM, Polito AJ, Liu MC, Danoff SK, Lechtzin N: Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med 2012, 157:398-406.
• [19]King TE Jr, Behr J, Brown KK, Du Bois RM, Lancaster L, De Andrade JA, Stähler G, Leconte I, Roux S, Raghu G: BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008, 177:75-81.
• [20]King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, Du Bois RM: Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009, 374:222-228.
• [21]Lechtzin N, Hilliard ME, Horton MR: Validation of the Cough Quality-of-Life Questionnaire in patients with idiopathic pulmonary fibrosis. Chest 2013, 143:1745-1749.
• [22]Mishra A, Bhattacharya P, Paul S, Paul R, Swarnakar S: An alternative therapy for idiopathic pulmonary fibrosis by doxycycline through matrix metalloproteinase inhibition. Lung India 2011, 28:174-179.
• [23]Naji NA, Connor MC, Donnelly SC, McDonnell TJ: Effectiveness of pulmonary rehabilitation in restrictive lung disease. J Cardiopulm Rehabil 2006, 26:237-243.
• [24]Nishiyama O, Taniguchi H, Kondoh Y, Kimura T, Ogawa T, Watanabe F, Nishimura K: Health-related quality of life in patients with idiopathic pulmonary fibrosis. What is the main contributing factor? Respir Med 2005, 99:408-414.
• [25]Nishiyama O, Kondoh Y, Kimura T, Kato K, Kataoka K, Ogawa T, Watanabe F, Arizono S, Nishimura K, Taniguchi H: Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology 2008, 13:394-399.
• [26]Noth I, Anstrom KJ, Calvert SB, De Andrade J, Flaherty KR, Glazer C, Kaner RJ, Olman MA: A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012, 186:88-95.
• [27]Patel AS, Siegert RJ, Brignall K, Gordon P, Steer S, Desai SR, Maher TM, Renzoni EA, Wells AU, Higginson IJ, Birring SS: The development and validation of the King’s Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax 2012, 67:804-810.
• [28]Peng S, Li Z, Kang J, Hou X: Cross-sectional and longitudinal construct validity of the Saint George’s Respiratory Questionnaire in patients with IPF. Respirology 2008, 13:871-879.
• [29]Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, King TE Jr: A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004, 350:125-133.
• [30]Raghu G, Brown KK, Costabel U, Cottin V, Du Bois RM, Lasky JA, Thomeer M, Utz JP, Khandker RK, McDermott L, Fatenejad S: Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008, 178:948-955.
• [31]Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, Martinez FJ, Nathan SD, Wells AU, Collard HR, Costabel U, Richeldi L, De Andrade J, Khalil N, Morrison LD, Lederer DJ, Shao L, Li X, Pedersen PS, Montgomery AB, Chien JW, O’Riordan TG: Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med 2013, 158:641-649.
• [32]Rammaert B, Leroy S, Cavestri B, Wallaert B, Grosbois JM: Home-based pulmonary rehabilitation in idiopathic pulmonary fibrosis. Rev Mal Respir 2009, 26:275-282.
• [33]Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G, Brun M, Gupta A, Juhel N, Klüglich M, Du Bois RM: Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011, 365:1079-1087.
• [34]Swigris JJ, Brown KK, Behr J, Du Bois RM, King TE, Raghu G, Wamboldt FS: The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med 2010, 104:296-304.
• [35]Swigris JJ, Han M, Vij R, Noth I, Eisenstein EL, Anstrom KJ, Brown KK, Fairclough D: The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis. Respir Med 2012, 106:1447-1455.
• [36]Tzanakis N, Samiou M, Lambiri I, Antoniou K, Siafakas N, Bouros D: Evaluation of health-related quality-of-life and dyspnea scales in patients with idiopathic pulmonary fibrosis. Correlation with pulmonary function tests. Eur J Intern Med 2005, 16:105-112.
• [37]Tzouvelekis A, Paspaliaris V, Koliakos G, Ntolios P, Bouros E, Oikonomou A, Zissimopoulos A, Boussios N, Dardzinski B, Gritzalis D, Antoniadis A, Froudarakis M, Kolios G, Bouros D: A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. J Transl Med 2013, 11:171. BioMed Central Full Text
• [38]Verma G, Marras T, Chowdhury N, Singer L: Health-related quality of life and 6 min walk distance in patients with idiopathic pulmonary fibrosis. Can Respir J 2011, 18:283-287.
• [39]Yorke J, Swigris J, Russell AM, Moosavi SH, Ng Man Kwong G, Longshaw M, Jones PW: Dyspnea-12 is a valid and reliable measure of breathlessness in patients with interstitial lung disease. Chest 2011, 139:159-164.
• [40]Zimmermann CS, Carvalho CR, Silveira KR, Yamaguti WP, Moderno EV, Salge JM, Kairalla RA, Carvalho CR: Comparison of two questionnaires which measure the health-related quality of life of idiopathic pulmonary fibrosis patients. Braz J Med Biol Res 2007, 40:179-187.
• [41]Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW: A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010, 363:620-628.
• [42]Mahler DA, Weinberg DH, Wells CK, Feinstein AR: The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984, 85:751-758.
• [43][www.fda.gov/ downloads/ Drugs/ GuidanceComplianceRegulatoryInforma tion/ Guidances/ UCM193282.pdf] webcite US Department of Health and Human Services (USDHHS): Guidance for Industry. In Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims..
• [44]Jones PW: Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 2002, 19:398-404.
• [45]Jones PW: St. George’s Respiratory Questionnaire: MCID. COPD 2005, 2:75-79.
• [46]Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA: Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med 2014, 189:250-255.
• [47]Kew KM, Mavergames C, Walters JA: Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013., 10
• [48]Cope S, Capkun-Niggli G, Gale R, Jardim JR, Jansen JP: Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease–a network meta-analysis. Int J Chron Obstruct Pulmon Dis 2011, 6:329-344.